ERAS — Erasca, Inc. Stock Price, Chart & AI Report

Negative Jan 26, 2026 • 12:52 UTC Benzinga • Vandana Singh

Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?

Erasca (ERAS) stock declined 7.33% on Monday following news that Merck ended acquisition discussions with competitor Revolution Medicines over valuation disagreements. The deal would have valued Revolution Medicines at approximately $30 billion. Both companies develop RAS-pathway cancer therapies, and the failed deal sparked investor concerns about the sector's valuation environment.

ERAS MRK RVMD RVMDW Erasca Revolution Medicines Merck cancer drug

Sentiment note

Stock trading down 7.33% on Monday due to negative sentiment spillover from Merck's failed acquisition of competitor Revolution Medicines, raising concerns about valuation discipline in the RAS-pathway oncology sector where Erasca operates.

Positive Jan 23, 2026 • 21:01 UTC Benzinga • Globe Newswire

Erasca Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Erasca Inc (NASDAQ: ERAS), a clinical-stage precision oncology company, announced the successful closing of its upsized public offering of 25.875 million shares at $10.00 per share, generating approximately $258.8 million in gross proceeds. The company plans to use the net proceeds to fund research and development of its RAS/MAPK pathway-driven cancer therapies and for general corporate purposes.

ERAS public offering capital raise precision oncology RAS/MAPK pathway clinical-stage cancer therapies

Sentiment note

The company successfully completed an upsized public offering, raising $258.8 million in gross proceeds. The full exercise of underwriters' option and upsizing of the offering indicates strong investor demand. The capital raise provides substantial funding for R&D and operations, which is positive for a clinical-stage biotech company's ability to advance its pipeline.

Positive Jan 22, 2026 • 01:54 UTC GlobeNewswire Inc. • Na

Erasca Announces Pricing of Upsized Public Offering of Common Stock

Erasca, Inc., a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced the pricing of an upsized public offering of 22.5 million shares at $10.00 per share, generating $225 million in gross proceeds. The offering is expected to close on January 23, 2026, with proceeds to be used for R&D of product candidates and general corporate purposes.

ERAS public offering precision oncology RAS/MAPK pathway capital raise clinical-stage common stock

Sentiment note

The company successfully upsized its public offering from the initially proposed $150 million to $225 million, indicating strong investor demand and confidence. The capital raise provides substantial funding for R&D activities and supports the company's mission to develop therapies for RAS/MAPK pathway-driven cancers.

Positive Jan 14, 2026 • 15:52 UTC Benzinga • Prnewswire

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.

ONCY NRIX ERAS FHTX precision oncology patent cliff biotech acquisitions clinical trials

Sentiment note

Reported promising early clinical data for pan-RAS molecular glue ERAS-0015 with multiple confirmed responses at low doses, demonstrating potential differentiation from competitors, with Phase 1 data expected in H1 2026.

Neutral Aug 13, 2025 • 02:16 UTC The Motley Fool • Na

Erasca Narrows Loss 46% in Fiscal Q2

Clinical-stage biotech Erasca reported Q2 2025 results, highlighting reduced operating expenses and progress in two RAS-pathway cancer therapy clinical trials entering Phase 1, while maintaining a strong cash position to fund operations through 2028.

ERAS biotechnology cancer therapy RAS/MAPK pathway clinical trials research and development

Sentiment note

Mixed financial performance with reduced expenses and net loss, but no revenue and ongoing early-stage clinical development. Positive aspects include cash reserves and clinical trial progress, balanced by lack of immediate commercial products.

Positive May 29, 2025 • 12:00 UTC GlobeNewswire Inc. • Na

Erasca to Present at Upcoming Investor Conferences in June

Erasca, a clinical-stage precision oncology company, announced the advancement of its RAS-targeting franchise, with IND clearance for ERAS-0015 and IND submission for ERAS-4001, both ahead of schedule. The company expects to report Phase 1 monotherapy data for both programs in 2026 and has a projected cash runway of more than 3 years.

ERAS Erasca RAS-targeting ERAS-0015 ERAS-4001 Phase 1 cash runway

Sentiment note

The article highlights Erasca's progress in advancing its RAS-targeting franchise, with IND clearance and submission for its lead programs, as well as a strong projected cash runway. This suggests the company is making positive strides in its clinical development and financial position.

Positive Jan 31, 2025 • 13:00 UTC GlobeNewswire Inc. • N/A

Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference

Erasca, Inc. (ERAS), a clinical-stage precision oncology company focused on RAS/MAPK pathway-driven cancers, announced its participation in the Guggenheim Securities SMID Cap Biotech Conference, where management will present and hold one-on-one investor meetings.

ERAS Erasca precision oncology RAS/MAPK pathway cancer biotech conference

Sentiment note

The article highlights Erasca's participation in an industry conference, which suggests the company is actively engaged in its business and pursuing growth opportunities. The company's focus on developing therapies for RAS/MAPK pathway-driven cancers is also a positive, as this is a significant area of research in the oncology field.

Positive Dec 26, 2024 • 16:26 UTC Benzinga • Prnewswire

Oncology in Focus: How Emerging Therapies Are Reshaping Cancer Treatment

The oncology field is advancing with emerging immunotherapies and AI-driven personalized cell therapies. Key players like Oncolytics Biotech, Erasca, Allogene Therapeutics, Context Therapeutics, and Recursion Pharmaceuticals are driving progress in areas like breast, GI, and renal cell cancers.

ONCY ERAS ALLO CNTX oncology immunotherapy AI personalized cell therapy

Sentiment note

Erasca is reported to have made significant progress across its pipeline, including positive Phase 1b data for naporafenib plus trametinib in NRAS-mutant melanoma and advancements in its pan-RAS and pan-KRAS inhibitor programs.

Positive Nov 5, 2024 • 13:00 UTC GlobeNewswire Inc. • N/A

Erasca to Present at Upcoming Investor Conferences

Erasca, a clinical-stage precision oncology company, announced its participation in upcoming investor conferences, including the Guggenheim Securities Healthcare Innovation Conference, Jefferies London Healthcare Conference, and the 7th Annual Evercore HealthCONx Conference.

ERAS Erasca precision oncology investor conferences

Sentiment note

The article highlights Erasca's participation in multiple investor conferences, which suggests the company is actively engaging with the investment community and is likely confident in its business prospects.

Unknown Jun 4, 2024 • 13:55 UTC Zacks Investment Research • Zacks Equity Research

Should You Buy Erasca, Inc. (ERAS) After Golden Cross?

Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?

ERAS

Unknown May 21, 2024 • 20:05 UTC GlobeNewswire Inc. • Erasca, Inc.

Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional shares. All of the shares in the offering were sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, were approximately $184.0 million.

ERAS Financing Agreements Health

Unknown May 17, 2024 • 00:02 UTC GlobeNewswire Inc. • Erasca, Inc.

Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors

ERAS Licensing Agreements Clinical Study